TACE联合生长激素对肝癌患者免疫功能及预后影响.docVIP

TACE联合生长激素对肝癌患者免疫功能及预后影响[摘要] 目的 探讨肝动脉化疗栓塞（TACE）联合生长激素对肝癌患者免疫功能及预后的影响。方法 入选的50例原发性肝癌患者随机分成研究组（TACE治疗+生长激素）和对照组（TACE治疗）各25例。结果 研究组25例患者的有效率（36.0%）高于对照组（16.7%），研究组治疗后IgG、IgM均较治疗前明显升高，CD4+也较治疗前明显升高，而CD8+较治疗前明显降低，CD4+/CD8+比值较治疗前明显升高，差异有统计学意义（P＜0.05）。但对照组治疗后不同时间上述免疫学指标变化不明显，差异无显著性。两组随访后，研究组的生存率高于对照组（P＜0.05）。结论 TACE联合生长激素对肝癌患者疗效确切，能明显改善患者的免疫功能，提高肝癌患者的生存率，值得推广和应用。 [关键词] 原发性肝癌；肝动脉化疗栓塞（TACE）；生长激素；细胞免疫功能；预后 [中图分类号] R735.7[文献标识码]A [文章编号] 1673-9701（2011）27-01-02 The Impact of TACE Combined Growth Hormone on Immune Function andPrognosis of Patients with Hepatocellular Carcinoma LIZhiqiang The 1st Surgical Department，Liaocheng International Peace Hospital，Liaocheng 252000，China [Abstract] Objective To evaluate the hepatic arterial chemoembolization （TACE） combined growth hormone on immuneand prognosis function in hepatocellular carcinoma patients. Methods All 50 cases primary liver cancer were randomly divided into study group （TACE + growth hormone treatment） and control group （TACE treatment） of 25 cases. Results The study group of 25 patients of response rate（36.0%） was higher than control group（16.7%），after treatment，IgG，IgM of the study group was significantly higher than those before treatment，CD4+ also significantly was higher than that before treatment，while CD8+ was reduced more significantly，CD4+/CD8+ratio was significantly higher than that before treatment，the difference was statistically significant（P＜0.05）. The control group at different times after treatment，the immunological parameters had not change significantly，the difference was not significant.After follow-up one or two years, study group survival rate was higher than the control group（P＜0.05）. Conclusion TACE combined growth hormone is effective in patients with liver cancer，and it can significantly and improve the patient’s immune function， and improve the survival rate of liver cancer patients， should be promoted and applied. [Key words] Primary liver cancer；Hepatic artery chemoembolizat